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Abstract: Mycobacterium avium subspecies paratuberculosis (Map) is the etiologic agent of Johne’s
disease in ruminants and has been associated with Crohn’s disease in humans. An effective control
of Map by either vaccines or chemoprophylaxis is a paramount need for veterinary and possibly
human medicine. Given the importance of fatty acids in the biosynthesis of mycolic acids and the
mycobacterial cell wall, we tested novel amphiphilic C10 and C18 cyclobutene and cyclobutane fatty
acid derivatives for Map inhibition. Microdilution minimal inhibitory concentrations (MIC) with 5 or
7 week endpoints were measured in Middlebrook 7H9 base broth media. We compared the Map MIC
results with those obtained previously with Mycobacterium tuberculosis and Mycobacterium smegmatis.
Several of the C18 compounds showed moderate efficacy (MICs 392 to 824 µM) against Map, while a
higher level of inhibition (MICs 6 to 82 µM) was observed for M. tuberculosis for select analogs
from both the C10 and C18 groups. For most of these analogs tested in M. smegmatis, their efficacy
decreased in the presence of bovine or human serum albumin. Compound 5 (OA-CB, 1-(octanoic
acid-8-yl)-2-octylcyclobutene) was identified as the best chemical lead against Map, which suggests
derivatives with better pharmacodynamics may be of interest for evaluation in animal models.
Keywords: cis-C18 fatty acids; cyclobutane derivatives; cyclobutene derivatives; growth inhibition;
Mycobacterium avium subsp. paratuberculosis
1. Introduction
Johne’s disease (JD) is caused by Mycobacterium avium subspecies paratuberculosis (Map), and is
characterized by enteritis that affects ruminant species and wildlife. The disease has a global distribution
and is a significant problem for the livestock and associated industries [1]. Recent reports have suggested
a link to Crohn’s disease, raising concerns that Map is a zoonotic and/or food-borne pathogen [2]. As
a result, identification of effective methods for control of JD is important in terms of trade, public
health, and national agrosecurity [3]. Although an effective control of JD remains a major challenge,
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control strategies are continuously being revised, including the use of vaccines and therapeutic drugs
for treatment and/or chemoprophylaxis [4]. In the context of JD, vaccines and chemoprophylactic
approaches are suitable for use in the field, while treatment options are primarily considered for
high-value breeding stock animals. If Map is eventually demonstrated to cause at least a subset of
Crohn’s disease cases, Map chemotherapeutics could become important human medicinal agents.
Although standard drugs used for treatment of Mycobacterium tuberculosis (Mtb) do not have
the same efficacy on microorganisms of the Mycobacterium avium group, antimycobacterial agents
such as isoniazid (Inh) and clofazimine have been used, on an extra-label basis, to treat JD in
animals of significant economic value [5,6]. Monensin, a polyether antibiotic, has also been used for
prophylaxis in calves and to reduce fecal shedding in Map-infected animals [7]. However, the number
of chemotherapeutic agents that can be used either for prophylaxis or treatment remains limited.
There is a long history on the development of fatty acids and related compounds as potential
chemotherapeutic agents against mycobacteria [8,9]. In previous studies, we reported the chemical
synthesis of a novel series of amphiphilic cyclobutene and cyclobutane fatty acid derivatives possessing
substantial in vitro efficacy against Mtb and limited off-target toxicity [10]. Mycobacteria are known
to directly incorporate fatty acids into mycolic acid biosynthesis [11], and a number of classical
mycobacterial drugs, including Inh and ethionamide, target this essential process [12]. The presence
of mycolic acids is a general feature of mycobacteria; however, different mycobacterial species have
specific structures that could affect the efficacy of various fatty acid derivatives [13]. Our hypothesis
is that uptake of the modified fatty acids results in the inhibition of mycolic acid biosynthesis by an
uncharacterized mechanism. Thus, those inhibition-associated alterations in the cell wall structure
may lead to lethality, increased susceptibility to antibiotics or the host immune system, or decreased
pathogen virulence.
Cyclobutanes can be found within the structures of a large number of natural products and
the backbone of the clinically used anticancer drug carboplatin [14–17]. Although the enhanced
reactivity of cyclobutenes and cyclobutanes compared to unstrained cycloalkanes makes both groups
valuable as synthetic intermediates [18], neither functionality is particularly fragile. Our previous work
investigated two series of highly specific fatty acid derivatives, one based on decenoic acid (C10) and
the other on oleic/elaidic acids (C18) [10]. We also demonstrated that these carbocylic analogs withstood
routine synthetic processing and brief heating to temperatures of at least 100 ◦C [19]. We found active
compounds from each series that had lower minimal inhibitory concentrations (MICs) against Mtb on
a molar basis compared to Inh. In this manuscript, we report the inhibitory properties of fatty acid
compounds on Map.
2. Materials and Methods
2.1. Bacterial Strains and Culture Conditions
Wild-type strains utilized in this study were the original virulent clinical isolate of Map K-10 [20]
and Mycobacterium smegmatis (Msm) mc2155 [21]. Map cultures were grown standing at 37 ◦C in
complete Difco™ Middlebrook 7H9 base broth (Becton, Dickinson and Company; Sparks, MD, USA),
adjusted to pH 5.9, and supplemented with oleic acid/albumin/dextrose complex (BBL™; Becton
Dickinson Microbiology Systems, Franklin Lakes, NJ, USA), ferric mycobactin J (Allied Monitor;
Fayette, MO, USA) and Tween® 80, as previously described [20]. Msm cultures were grown at 37 ◦C
with shaking (200 rpm; Innova 4300 incubator shaker; New Brunswick Scientific; Edison, NJ, USA) in
complete 7H9 broth supplemented with albumin/dextrose complex and Tween® 80, as described [22].
Cultures were grown to an OD600 between 0.6 and 1.2.
2.2. Fatty Acid Derivatives
The fatty acid derivatives, illustrated in Table 1 and Figure 1, were prepared using straightforward
procedures. Depending upon the target structure, between three and six synthetic steps were required
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to synthesize these compounds in the laboratory [10], which can readily be scaled-up for drug industry
development. 1D 1H NMR spectroscopy was used to verify the chemical purity of these fatty acids.
Four of the molecules (DA-CB, 1; DA-satCB, 2; OA-CB, 5; and OA-satCB, 6) are single diastereomeric
compounds, while DA-alcCB (4) is a mixture of two diastereomers differing in the stereochemistry
of the hydroxyl (OH) group. Derivatives OA-alcCB (8), OA-ketoCB (7), and EA-ClketoCB (11) are
mixtures of regioisomers in terms of the position of the substituents on the ring relative to the “head”
and “tail” of the fatty acid structure; the latter two are each a mixture of two diastereomers. All of
the compounds are racemic, except for DA-satCB (2), which is achiral. The antituberculosis drug
D-cycloserine (DCS; Sigma Life Science; St. Louis, MO, USA) was used for comparative purposes.
Table 1. Fatty acid derivatives used in this study.
No. AbbreviatedName 2
Compound Full Chemical
Name Formula Weight
Scaffold,
Functionality
1 DA-CB 8-(2-Cyclobuten-1-yl)octanoicacid 196.3 C10, alkene
2 DA-satCB 8-Cyclobutyloctanoic acid 198.3 C10, alkane
4 1 DA-alcCB 3-(Octanoic acid)cyclobutanol 214.3 C10, alcohol
5 OA-CB 1-(Octanoicacid-8-yl)-2-octylcyclobutene 308.5 cis-C18, alkene
6 OA-satCB cis-9,10-Ethanooctadecenoicacid 310.5 cis-C18, alkane
7 OA-ketoCB 3-(Octanoicacid-8-yl)-2-octylcyclobutanone 324.5 cis-C18, ketone
8 OA-alcCB 3-(Octanoicacid-8-yl)-2-octylcyclobutanol 326.5 cis-C18, alcohol
11 EA-ClketoCB 2-Chloro-3-(octanoicacid-8-yl)-4-octylcyclobutanone 358.9
trans-C18,
chloroketone
12 DA Decenoic acid 170.2 C10, alkene(acyclic)
DCS D-cycloserine 102.1
1 For the current study, this compound was only tested in Map. 2 CB = cyclobutene, satCB = saturated cyclobutene
(cyclobutane), alcCB = cyclobutanol, OA = oleic acid, ketoCB = cyclobutanone, EA = elaidic acid, and ClketoCB
= chlorocyclobutanone.
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2.3. Drug Susceptibility Assays
MICs were determined by the 96-well microtiter plate method with three technical and three
biological replicates, as previously described [22]. Once the bacteria reached the proper OD600, cells
were washed twice in 7H9 base broth, 25 mM/L glycerol, and 0.02% v/v tyloxapol. For Map, 2.0 mg/L
ferric mycobactin J was also added. Cells were vortexed for one minute with 4.0 mm glass beads to
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disrupt any clumps that may have formed during the centrifugation and washing steps. Map cells were
inoculated at an initial concentration of ca. 2.5 × 106 or 2.5 × 105 colony forming units (CFU)/well, and
the microtiter plates were incubated at 37 ◦C for 5 or 7 weeks, respectively. Msm cells were inoculated
at ca. 1.0 × 105 CFU/ml, recording results after 4 days at 37 ◦C, as described [10]. The initial inocula
were plated to quantify retrospectively CFU/ml for each strain and level.
We tested eight fatty acid derivatives against Map and seven against Msm, as well as decenoic
acid (DA, 12); in all cases, the compounds were prepared as solutions in 100% DMSO-d6 (Sigma Life
Science). For Map, the doubling dilution gradients were prepared from 16 to 1024 µg/ml, adjusting
the concentration of DMSO-d6 in all wells to 1.024% v/v. For Msm, the doubling dilution gradients
were prepared from 32 to 2048 µg/ml, which corresponded to 2.048% v/v of DMSO-d6. MIC differences
for a given compound are considered significant when values differ by at least 2 doubling dilutions.
At these concentrations, DMSO-d6 had no growth inhibitory effect on either Map or Msm cells. In
addition, the potential interference of serum albumins in MIC assays against Msm was analyzed in a
separate experiment by supplementing the media with various concentrations of Fraction V bovine
serum albumin (BSA; Fisher Scientific Fair Lawn, NJ, USA) or human serum albumin (HSA; Sigma
Life Science).
3. Results
3.1. Inhibitory Activity of Fatty Acid Derivatives against Msm
As Map does not grow well in the defined minimal media used in our previous studies [10],
we first compared the susceptibility of a control strain, Msm mc2155, in Middlebrook 7H9 base broth.
This broth contains, in addition to the minimal media components, L-glutamic acid, sodium citrate,
pyridoxine, biotin, and copper sulfate. As complete Middlebrook 7H9 contains albumin, we also
compared the effects of supplementing additional amounts of albumin to the base broth. Establishing
MIC values in the presence of BSA and/or HSA, conditions relevant to mammalian serum, is important
in interpreting in vitro and in vivo compound efficacy data for potential applications to veterinary or
human medicine. DCS, an effective second-line antituberculosis drug, was employed as a point of
reference against the unknown inhibitors.
Experimental results are presented in Table 2. The MICs measured in the presence of increasing
levels of BSA or HSA fell within a narrow concentration range. Moreover, MICs for the majority of the
analogs differed at most by one doubling dilution compared to values previously obtained in minimal
media without albumin (Table 2, Columns 2, 3, and 7). These differences are within the experimental
error of this assay as indicated by the two replicates, all measured at day 4 post-inoculation in the same
media but performed at different times (Table 2, Columns 3 and 7). In contrast, the MICs of OA-CB (5)
and EA-ClketoCB (11) were significantly different in Middlebrook 7H9 base broth and minimal media.
Albumins, which are known to strongly bind fatty acids [23,24], are expected to protect the
microorganisms from drug activity, with concomitant decrease in susceptibilities and increased MICs.
We tested both BSA (Table 2, Columns 4–6) and HSA (Table 2, Columns 8–10) at 0.125, 0.25, and 0.5%
w/v. The C10 compound (DA-CB, 1), the control C10 decenoic acid parent compound (DA, 12), and
DCS displayed the same MICs or values within one doubling dilution for both BSA and HSA at all
concentrations tested. Similar behavior was also observed for DA-satCB (2) and OA-CB (5) with HSA
and BSA, respectively. Compounds OA-satCB (6), OA-ketoCB (7), OA-alcCB (8), and EA-ClketoCB (11)
displayed significant differences in MICs in the range of two to three doubling dilutions for both BSA
and HSA. In addition, the MICs for fatty acid derivatives DA-satCB (2) and OA-CB (5) varied by two
or more doubling dilutions for BSA and HSA, respectively. In general, the effect of albumins reached a
saturation point at 0.25% without further changes in MICs.
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Table 2. Minimal inhibitory concentration (MIC) values [µg/ml (µM)] against Mycobacterium smegmatis
(Msm) with and without bovine serum albumin (BSA) and human serum albumin (HSA) at day 4.
No.
Minimal
Media
1
No
BSA 2
0.125%
BSA
0.25%
BSA
0.5%
BSA
No
HSA 2
0.125%
HSA
0.25%
HSA
0.5%
HSA
1 512(2608)
512
(2608)
512
(2608)
512
(2608)
512
(2608)
512
(2608)
1024
(5217)
1024
(5217)
1024
(5217)
2 512(2582)
256
(1291)
512
(2582)
1024
(5164)
1024
(5164)
512
(2582)
512
(2582)
1024
(5164)
1024
(5164)
5 128(415)
1024
(3319)
2048
(6639)
2048
(6639)
2048
(6639)
512
(1660)
1024
(3319)
2048
(6639)
>2048
(>6639)
6 256(824)
512
(1649)
1024
(3298)
1024
(3298)
2048
(6596)
512
(1649)
2048
(6596)
2048
(6596)
2048
(6596)
7 128(394)
256
(789)
512
(1578)
1024
(3156)
1024
(3156)
256
(789)
512
(1578)
1024
(3156)
1024
(3156)
8 256(784)
256
(784)
512
(1568)
1024
(3136)
1024
(3136)
256
(784)
1024
(3136)
1024
(3136)
2048
(6272)
11 128(357)
1024
(2853)
2048
(5706)
>2048
(>5706)
>2048
(>5706)
512
(1426)
1024
(2853)
2048
(5706)
2048
(5706)
12 512(3007)
1024
(6015)
1024
(6015)
1024
(6015)
1024
(6015)
1024
(6015)
2048
(12029)
2048
(12029)
2048
(12029)
DCS 64 (627) 128(1254)
128
(1254)
128
(1254)
128
(1254)
128
(1254)
128
(1254)
128
(1254)
128
(1254)
1 Data taken from [10]. 2 Data represents replicated experiments carried out at different times.
3.2. Inhibitory Activity of Fatty Acid Derivatives against Map
To test Map susceptibility, we supplemented the 7H9 base broth with ferric mycobactin J,
as described in Section 2.3. The results for both 5 and 7 week endpoints (Table 3, Columns 2 and 3)
indicated no significant differences since, at most, MICs differed by one doubling dilution. Specifically,
the longer-chain “OA” compounds OA-CB (5), OA-ketoCB (7), and OA-alcCB (8) were active with
MICs of ca. 400 µM. The “DA” shorter-chain fatty acid derivatives DA-CB (1) and DA-satCB (2) were
less active with MICs of ca. 1300 µM or higher. Intermediate MIC activity of 713 µM was seen for the
analog based upon the elaidic acid framework (EA-ClketoCB, 11). DCS displayed activity similar to
the less effective compounds with MICs of 2508 and 1254 µM for weeks 5 and 7, respectively.
Table 3. MICs [µg/ml (µM)] againstMycobacterium tuberculosis (Mtb) andMycobacterium avium subspecies
paratuberculosis (Map).
Compound # Map K-10 Week 5 Map K-10 Week 7 Mtb CDC15511 Week 7
Mtb H37Rv 1
Week 7
1 512 (2608) 256 (1304) 16 (82) 16 (82)
2 256 (1291) 256 (1291) 4 (20) 4 (20)
4 >1024 (>4778) >1024 (>4778) 64 (299) 128 (597)
5 128 (415) 128 (415) 128 (415) 16 (52)
6 512 (1649) 256 (824) 8 (26) 16 (52)
7 128 (394) 128 (394) 64 (197) 32 (99)
8 128 (392) 128 (392) 8 (24) 2 (6)
11 256 (713) 256 (713) 256 (713) 256 (713)
12 1024 (6015) 512 (3007) 32 (188) 32 (188)
DCS 256 (2508) 128 (1254) 4 (39) 8 (78)
1 Data taken from [10].
As indicated above in Table 2 for the Msm mc2155 wild-type, the differences in media compositions
were minor and did not affect the MICs. Thus, we also compared the Map week 7 results with those
previously obtained with Mtb [10]. In general, Mtb was more susceptible to the fatty acid derivatives
and DCS than Map. For example, while OA-alcCB (8) was one of the best inhibitors for both Map
Vet. Sci. 2019, 6, 46 6 of 10
and Mtb, MICs against Map were 16- to 65-fold greater than than those for Mtb strains CDC1551 and
H37Rv, respectively. In terms of relative efficacy within the series of analogs, DA-CB (1), DA-satCB (2),
OA-satCB (6), and OA-alcCB (8) have MICs < 100 µM against Mtb. Fatty acid derivatives OA-CB (5),
OA-ketoCB (7), and OA-alcCB (8) displayed MICs < 500 µM against Map. Compounds DA-satCB (2),
OA-satCB (6), and OA-alcCB (8) proved to have greater activity than DCS towards Mtb; the same was
true in Map for OA-CB (5), OA-satCB (6), OA-ketoCB (7), OA-alcCB (8), and EA-ClketoCB (11). Fatty
acid derivative EA-ClketoCB (11), while exhibiting identical MICs (713 µM) for Map and Mtb, is one of
the least effective Mtb inhibitors, but is still a moderate inhibitor of Map. Likewise, DA-satCB (2) was
highly effective against both Mtb strains, but had a lower efficacy against Map.
4. Discussion
This study demonstrated that fatty acid analogs previously shown to inhibit Mtb growth also
inhibited Map growth, except compound 4 (DA-alcCB), which had an MIC > 4778 µM. However,
there are major differences in the MICs and the compound structures that were more active against
each species. The four most active fatty acid derivatives tested against Mtb had MICs in the range of
20–82 µM. In contrast, the three analogs displaying the greatest activity against Map have MICs of
392–415 µM. The control compound (DA, 12) was moderately active (MIC 188 µM) against Mtb, but
this compound was essentially inactive against Map with MICs above 3000 µM. The one exception to
this trend is chloroketone (EA-ClketoCB, 11), which has the same MIC (713 µM) against Mtb and Map.
Our investigations with Mtb found good inhibitory activity for analogs in both the C10 and C18 series;
whereas, the analogs with the lowest MICs against Map came exclusively from the C18 series derived
from oleic acid. Three of the four analogs most active against both Mtb strains (MICs < 100 µM) are
based upon a simple cyclobutene (DA-CB, 1) or cyclobutane (DA-satCB, 2; OA-satCB, 6) structure. Of
note, the C18 oleic acid parent compound is not inhibitory for Map since oleic acid is an enrichment
recommended for complete Middlebrook media. Regarding the three analogs most active against Map,
OA-CB (5) is a simple cyclobutene, while the other two contain oxygen-functionalized cyclobutanes
(OA-ketoCB, 7; and OA-alcCB, 8). Two analogs screened against E. coli G58-1—OA-satCB (6) and
DA-CB (1)—had weak inhibition at concentrations up to 2608 µM [10]. Thus, these compounds may
inhibit a specific metabolic pathway unique to mycobacteria.
In the earlier studies with Mtb [10], we observed that most analogs tested here were more active
in minimal than in rich media (LB broth), suggesting that interactions of fatty acids with albumins or
other media components could result in reduced efficacy. In our current studies, we tested the effects
of albumins using Msm as a model system. BSA or HSA supplementation had the greatest effect on
the efficacy of compounds 6 (OA-satCB), 7 (OA-ketoCB), 8 (OA-alcCB), and 11 (EA-ClketoCB). BSA or
HSA supplementation increased the MIC by two or more doubling dilutions. An albumin-associated
change was also observed for DA-satCB (2) and OA-CB (5). Despite the negative impact on MICs, the
use of albumins may increase the solubility of these fatty acid analogs, which, in turn, may facilitate
delivery into animals and improve pharmacokinetics, especially those properties related to absorption,
distribution, metabolism, and excretion (ADME) [25]. These Msm results suggest albumins may have
a similar impact on compound efficacy against Map and Mtb.
In evaluating which fatty acid analogs are the most promising leads to be developed into potential
Map treatments, compound hydrophobicity and aggregation must also be considered [26–28]. Critical
micellar concentrations (CMC) of four analogs in the C18 series (OA-satCB, 6; OA-ketoCB, 7; OA-alcCB,
8; and EA-ClketoCB, 11) have been established to be < 50 µM, while the CMC for compound 5 (OA-CB)
was between 50 and 100 µM. It is important to note that the CMCs are well below the MICs identified
here. The analogs in the C10 series (DA-CB, 1; DA-satCB, 2; and DA-alcCB, 4) have CMCs > 1000 µM,
which may or may not encompass some of the highest concentrations employed here. It should be
noted, however, that the CMCs were determined in a simple potassium phosphate alkaline buffer
with DMSO-d6 [10], and the CMCs will likely increase upon the addition of fat-solubilizing albumins.
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The albumin-associated solubilization may be relevant for in vivo testing of these derivatives [29],
especially for compounds whose MICs are least effected by albumins.
Fatty acid analogs investigated here, except compounds 7 (OA-ketoCB) and 11 (EA-ClketoCB),
were compared against DA (12), Inh, and DCS for cytotoxicity against RAW 264.7 murine macrophages
up to 250 µM, as shown in Table S1 of our previous manuscript [10]. In addition, the C18 oleic acid
parent compound was shown to be nontoxic for this cell line (Ji-Young Lee and Patrick Dussault
unpublished results). The analog concentration required to reduce cell viability below 50% proved to
be structure-dependent: DA-CB (1, ca. 100 µM); DA-satCB (2, ca. 50 µM); DA-alcCB (4, > 250 µM);
OA-CB (5, > 250 µM); OA-satCB (6, > 250 µM); OA-alcCB (8, < 25 µM); DA (12, ca. 200 µM); DCS
(> 250 µM); and Inh (> 250 µM). Compounds 5 (OA-CB) and 6 (OA-satCB) were less toxic against
murine macrophages, but displayed good to moderate activity against Map (Table 3). In contrast, fatty
acid derivative 8 (OA-alcCB) had good inhibitory activity against Map, but was relatively toxic against
RAW 264.7 cells. Moreover, supplementation with albumins may decrease fatty acid cytotoxicity; for
example, the presence of BSA and HSA reduced apoptotic effects induced by long chain omega-3
polyunsaturated fatty acids in HaCaT epidermal keratinocyte cells [30]. Overall, compound 5 (OA-CB)
was identified as the best chemical lead for further investigation. Chemical synthesis of derivatives of
this compound with better pharmacodynamics may be of interest for further evaluation and testing in
animal models.
We show that C18 fatty acid derivatives are better inhibitors of Map and, in general, both C10 and
C18 analogs exhibited higher activity against Mtb than Map (Table 3). We predict that the mechanism
of action for both C10 and C18 compounds is the ability to inhibit mycolic acid biosynthesis. In addition,
membrane fluidity affects the compounds ability to penetrate further into the mycomembrane. The
mycobacterial cell wall is comprised of mycolic acids that are essential high molecular weight α-alkyl,
β-hydroxy fatty acids [11,31,32]. There are different structural classes of mycolic acids (α-, methoxy and
keto-). The α-branch is saturated with typically 24 carbon atoms, while the meromycolate arm usually
contains 60 carbons. There are also species-specific differences, especially in the long meromycolate
arms. These characteristics affect membrane fluidity that is directly linked to the solubility of lipophilic
compounds. The main properties affecting fluidity are the length of meromycolate carbon chains
and the presence of conformational constraints in the form of cyclopropane units. The greater the
number of trans-cyclopropanations in the α-mycolic acids, the higher the melting point and the lower
its fluidity [31,33]. Regarding the species tested in this and our previous studies, the increasing order
of fluidity is M. avium > Msm > Mtb. Though this may not be the only reason, increased fluidity
may allow further penetration of C10 derivatives deep into the mycolic acid layer to potentially gain
access to the cytoplasmic membrane and the cytosol to inhibit key components of the mycolic acid
biosynthetic and/or transport machinery. The less fluid Msm and M. avium layers may allow for better
penetration of the more lipophilic C18 derivatives.
Differences in lipid metabolism between Msm, Map, and Mtb may also explain the greater
susceptibility of Mtb to these analogs. In Mtb, there is an expansion of genes involved in lipid
biosynthesis, while genes related to lipid degradation predominate in Msm and Map that have an
intermediate ratio of lipid biosynthetic and degradation genes [34]. Thus, the inhibition of lipid
biosynthesis in Mtb may be more critical and cause greater overall metabolic disruption. This resembles
the effect of Inh that has also a greater inhibitory effect on Mtb than on Msm or Map [35]. In this
interpretation, the fatty acid derivatives target(s) could be either in the essential cytoplasmic steps prior
to uptake by the conserved essential membrane trehalose monomycolate transporter MmpL3 or the
inhibition of the transporter itself [32,36]. In addition, the orthologous proteins from Mtb and Map are
not identical (e.g., 70% identity and 78% similarity for MmpL3) and may have different affinities for the
fatty acid derivatives. Our compounds were rationally designed to inhibit cyclopropanation reactions
that occur in the cytosol [10,32]. However, these enzymes are not likely to be potential targets since
mycobacterial cyclopropanases (e.g., CmaA1, CmaA2, Mma2, and Pca), though important in vivo,
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are not essential in vitro [37]. Thus, the inhibition of these enzymes may not account for microbial
growth inhibition.
5. Conclusions
In this study, we demonstrated that several members of a class of cyclobutene- or
cyclobutane-containing fatty acid derivatives based upon either C10 or C18 skeletons are inhibitory to
Map. In previous studies, these analogs have also been shown to inhibit growth of Msm and Mtb. In
contrast to the results with Mtb, where inhibition was observed with analogs from both the C10 and C18
series, only the C18 compounds displayed significant efficacy against Map. We also demonstrated in
Msm that the presence of albumins increases the MIC for some of the compounds. However, albumins
may also incease analog solubility, and the concomitant decrease in cytotoxicity might allow for higher
drug concentrations in vivo. While the level of inhibition displayed by these analogs against Map is
moderate, the results suggest that this family of fatty acid derivatives may be a useful starting point in
search of improved Map inhibitors. While we do not yet have a definitive explanation as to why Mtb is
more susceptible to these analogs than Map, the results described in this manuscript, and in particular,
the very different levels of inhibition observed with the two microorganisms across a common set
of inhibitors, may reveal insights into their mechanisms of action. In future experiments, we plan
to use metabolomic, biochemical, and genetic methods to validate the involvement of mycolic acid
biosynthesis in the mechanism of action of these compounds against mycobacteria and identify the
lethal target(s) affected. We also plan to determine the uptake of the fatty acid derivatives to identify
whether the inhibition occurs in the cytoplasmic steps or the transport process.
6. Patents
A pending patent application, “Amphiphilic Cyclobutenes and Cyclobutanes” (Publication
Number: US 2015/0175519 A1; Publication Date: Jun. 25, 2015; United States Application Number:
14/403,763), describes amphiphilic compounds containing a cyclobutene or cyclobutane moiety.
In some embodiments, the compounds are useful for treating infection by Mycobacterium such
as Mtb. Cyclobutene-containing compounds are also useful as monomers in the preparation of
amphiphilic polymers.
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